HU Hong, LIN Ying-yi. Ribociclib for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Luminal B Breast Cancer: CORALLEEN Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 88-91. DOI: 10.12019/j.issn.1671-5144.2023.02.005
|
Citation:
|
HU Hong, LIN Ying-yi. Ribociclib for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Luminal B Breast Cancer: CORALLEEN Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 88-91. DOI: 10.12019/j.issn.1671-5144.2023.02.005
|
HU Hong, LIN Ying-yi. Ribociclib for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Luminal B Breast Cancer: CORALLEEN Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 88-91. DOI: 10.12019/j.issn.1671-5144.2023.02.005
|
Citation:
|
HU Hong, LIN Ying-yi. Ribociclib for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Luminal B Breast Cancer: CORALLEEN Study[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 88-91. DOI: 10.12019/j.issn.1671-5144.2023.02.005
|
DownLoad: